Skip to main content
Terug
Watch Compare

OnKure Therapeutics, Inc.

Datakwaliteit: 83%
OKUR
Nasdaq Manufacturing Chemicals
€ 4,41
▲ € 0,03 (0,57%)
Marktkapitalisatie: 60,23 M
Prijs
€ 4,41
Marktkapitalisatie
60,23 M
Dagbereik
€ 4,25 — € 4,46
52-Weeksbereik
€ 1,70 — € 4,75
Volume
199.711
Openen € 4,39
50D / 200D Gem.
€ 3,18
38,37% above
50D / 200D Gem.
€ 2,85
54,36% above

Quick Summary

Belangrijkste Punten

Negative free cash flow of -51,87 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-82,32%
Onder sectorgemiddelde (-53,47%)
ROIC-68,56%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio11,45
Interest Coverage-18,34

Waardering

PE (TTM)
-1,01
Boven sectorgemiddelde (-1,47)
P/B Ratio0,91
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -1,0 -1,5
P/B 0,9 1,6
ROE % -82,3 -53,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

ETFs Holding This Stock

AVSC logo AVSC Avantis U.S. Small Cap Equity ETF
0,00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -59,52 M
ROE -82,32% ROA -74,91%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -51,87 M
ROIC -68,56% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 11,45
Interest Coverage -18,34 Asset Turnover N/A
Working Capital 65,28 M Tangible Book Value 66,43 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,01 Forward P/E N/A
P/B Ratio 0,91 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -86,12%
Market Cap 60,23 M Enterprise Value -10,10 M
Per Share
EPS (Diluted TTM) -4,40 Revenue / Share N/A
FCF / Share -3,79 OCF / Share -3,79
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 87,16%
SBC-Adj. FCF -61,31 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — 0,0 — — —
Net Income -59,52 M -52,67 M -77,39 M -51,96 M -39,77 M
EPS (Diluted) -4,40 -15,28 -2,52 -2,12 -2,19
Gross Profit — — — — —
Operating Income -62,95 M -54,39 M -83,05 M -53,85 M -39,82 M
EBITDA — — — — —
R&D Expenses 48,26 M 43,80 M 56,61 M 37,71 M 28,17 M
SG&A Expenses — — — — —
D&A 447.000,0 459.000,0 170.000,0 88.000,0 50.000,0
Interest Expense 3,43 M 1,71 M — — —
Income Tax 0,0 — 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 62,12 M 114,91 M 107,44 M 108,18 M 154,02 M
Total Liabilities 5,93 M 11,08 M 18,83 M 8,21 M 6,81 M
Shareholders' Equity 56,18 M 103,83 M 88,61 M 99,97 M 147,21 M
Total Debt — — — — —
Cash & Equivalents 59,05 M 110,76 M 27,63 M 19,93 M 124,66 M
Current Assets 60,84 M 113,00 M 106,62 M 106,35 M 153,73 M
Current Liabilities 5,92 M 10,53 M 18,18 M 7,12 M 6,20 M